SCHEDULE 13D/A: MPM BioImpact Group Reduces Stake in Repare Therapeutics Through Open Market Sales

A group of investment entities and individuals affiliated with MPM BioImpact LLC has significantly reduced their beneficial ownership in Repare Therapeutics Inc. through recent open market share sales.

Summary

• This Amendment No. 5 to Schedule 13D reports open market sales of Common Shares of Repare Therapeutics Inc. by a group of affiliated entities and individuals (the 'Filing Persons').
• The sales occurred between December 24, 2024, and January 3, 2025, with average sale prices ranging from $1.23 to $1.38 per share.
• Key selling entities included MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, and UBS Oncology Impact Fund L.P.
• A total of 642,324 Common Shares were sold across these entities during the reported period, at a weighted average price of approximately $1.31 per share.
• Following these sales, Ansbert Gadicke, a key individual within the group, beneficially owns 2,658,532 shares, representing 6.3% of the Issuer's common shares outstanding.
• MPM BioVentures 2014 LLC and its managing directors (Luke Evnin and Todd Foley) each beneficially own 1,535,644 shares, representing 3.6% of the outstanding shares.
• UBS Oncology Impact Fund L.P. and its related entities (Oncology Impact Fund (Cayman) Management L.P. and MPM BioImpact LLC) each beneficially own 1,122,888 shares, representing 2.6% of the outstanding shares.
• The calculation of beneficial ownership percentages is based on 42,510,708 Common Shares outstanding as of November 1, 2024, as reported in the Issuer's Form 10-Q filed on November 7, 2024.

Sentiment

Score: 3

Explanation: The sentiment is negative as a significant institutional investor group has reduced its stake in the company through open market sales, which can be interpreted as a lack of confidence or a strategic portfolio reallocation away from the issuer.

Negatives

• A significant reduction in beneficial ownership by a major institutional investor group, such as MPM BioImpact, can be perceived negatively by the market, potentially signaling a lack of confidence in the company's near-term prospects.
• The open market sales occurred at relatively low share prices, ranging from $1.23 to $1.38, which might suggest the investors were willing to exit at current valuations.

Risks

• The reported sales by a major investor group could lead to increased selling pressure on Repare Therapeutics' stock.
• Investor confidence may be negatively impacted by the divestment, potentially affecting the company's ability to raise future capital or its stock valuation.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Repare Therapeutics Inc.'s future operations or financial performance. It solely reports changes in beneficial ownership by an investor group.

Industry Context

This filing reflects a specific investment group's portfolio adjustments rather than broader industry trends. However, significant divestment by a biotech-focused fund could be interpreted by some as a signal of cautious sentiment within the oncology or precision medicine sector, though this is not explicitly stated in the filing.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential downward pressure on the stock price due to the divestment by a major investor.
• Potential Investors: May view the reduction in stake by an experienced biotech investor group as a cautionary signal, potentially impacting future investment decisions.

Key Dates

Recommendation

Keywords

SEC filing, Schedule 13D/A, beneficial ownership, share sales, institutional investor, Repare Therapeutics Inc., MPM BioImpact, UBS Oncology Impact Fund, biotechnology, pharmaceuticals